<DOC>
	<DOCNO>NCT00270634</DOCNO>
	<brief_summary>This study see voclosporin safe effective prevent kidney transplant rejection .</brief_summary>
	<brief_title>Study ISA247 ( Voclosporin ) De Novo Renal Transplantation</brief_title>
	<detailed_description>Prograf® ( tacrolimus ) associate numerous side effect , include neurotoxicity , nephrotoxicity , polyoma nephropathy , QT prolongation , New Onset Diabetes Mellitus After Transplant ( NODAT ) . Voclosporin novel calcineurin inhibitor intend use prevention organ graft rejection . Comparison ( ) : Voclosporin 3 dose level ( 0.4 , 0.6 , 0.8 mg/kg twice day ) compare tacrolimus</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Males female age 18 65 year inclusive time screen . Patients must receive first cadaveric living donor renal transplant . Patients must able receive oral medication time randomization . Females pregnant nursing planning become pregnant course study , 3 month last dose study medication . Sexuallyactive woman childbearing potential ( include &lt; 1 year postmenopausal ) sexuallyactive men practice highly effective method birth control . A highly effective method birth control define one result low failure rate ( i.e. , less 1 % per year ) use consistently correctly include implant , injectables , combine oral contraceptive , doublebarrier method , sexual abstinence , sterile partner . Sexuallyactive men woman childbearing potential continue practice contraception outline treatment ≥ 3 month last dose voclosporin . Able give write informed consent prior screen procedure . Able keep study appointment cooperate study requirement , opinion investigator . Receiving HLA ( human leukocyte antigen ) identical living relate transplant . Cold ischemic time &gt; 24 hour . Peak PRA ( panel reactive antibody ) &gt; 30 % Cadaveric donor age 60 , nonheart beat donor , cadaveric donor positive HIV , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) . Transplantation multiple graft ( e.g . kidney pancreas ) . Systemic infection require continued therapy time entry study . ( Prophylaxis cytomegalovirus [ CMV ] and/or pneumocystis carinii pneumonia ( PCP ) infection permit ) . Serologic evidence know latent human immunodeficiency virus ( HIV ) , hepatitis B ( HBV ) hepatitis C ( HCV ) virus . Known negative serology prior study entry may use . A current malignancy history malignancy within 5 year history lymphoma time . Subjects enrol history squamous basal cell carcinoma surgically excise remove curettage electrodesiccation . Requires prohibit medication treatment study . Alanine transaminase ( ALT ) , aspartate transaminase ( AST ) , gammaglutamyl transferase ( GGT ) ≥ 3x upper limit normal ( ULN ) time transplantation . White blood cell count ≤ 2.8 x 10^9/L . Triglycerides ≥ 3x ULN . Pregnant woman nurse mother . Has use investigational drug device within 28 day 5 half life ( whichever longer ) prior enrollment . Previous exposure voclosporin . A history active alcoholism drug addiction within 1 year prior study entry . Weighs &lt; 45 kg ( 99 lb ) &gt; 140 kg ( 308 lb ) . A history disease , include mental/emotional disorder would interfere subject 's participation study , might cause administration voclosporin pose significant risk subject , opinion investigator . Allergy iodine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Randomized Controlled Trials</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Adult</keyword>
	<keyword>Kidney Transplantation</keyword>
	<keyword>Treatment Outcome</keyword>
</DOC>